Abstract 245P
Background
Cervical cancer ranked second on women in Indonesia with 23.4/100,000 population incidence and 13.9/100,000 population mortality, emphasizing the importance of its screening and prevention. Indonesian government have applied cancer “see and treat” method with visual inspection using acetic acid (VIA) followed by cryotherapy procedure, but the number of women complying with the program were only 5% despite 80% target in 2013. This study aimed to explore factors influencing women with VIA positive result’s likelihood to receive cryotherapy.
Methods
Our cross-sectional study observed “see and treat” program at Temanggung District Health Office, Central Java, Indonesia, between March 29 and April 31, 2018. We used simple random sampling technique to select 356 VIA possitive women aged 30-50 years and collected data on whether they underwent cryotherapy, their demographic profile, education, knowledge and awareness about cryotherapy, and family support using structured questionnaire. Data were analyzed with chi square analysis on STATA software.
Results
In our study, 217 women (60.69%) received cryotherapy, while 139 women (39.04%) did not. Among all variables analysed, factors affecting subjects’ likelihood to underwent cryotherapy are knowledge about cryotherapy itself (PR = 0.776, 95%CI=0.660-0.913, p = 0.003), residence distance (PR = 0.795, 95%CI=0.650-0.971, p = 0.016), permission from family (PR = 0.675, 95%CI=0.556-0.820, p = 0.018), and accompaniment by their family (PR = 0.824, 95%CI=0.700-0.970, p = 0.026). Age, marital status, occupation, and education background did not show significant correlation with women’s decision to receive cryotherapy.
Conclusions
Our study showed that more individuals with VIA positive results were willing to receive cryotherapy as an effort to prevent cervical cancer. However, our study also showed knowledge about cryotherapy, residence distance, family permission and family accompaniment as factors lowering VIA possitive women’s likelihood to receive cryotherapy. Because this study is only limited on Temanggung population, further study is needed to explore larger population and other factors that might also influence this behavior.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Funding
Board for Development and Empowerment Human Resources of Health, Ministry of Health Republic of Indonesia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract